铜载体1有助于胆管癌的进展
Yanpeng Ma1, Longlong Liu1, Jiayue Duan1
1Department of General Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050005, Hebei, China.
Biochimica et biophysica acta. General subjects
|November 4, 2025
概括
铜载体SLC31A1 (CTR1) 通过调节铜,线粒体功能和氧化还原平衡,促进胆管癌 (CCA) 的进展. 针对SLC31A1可能为CCA患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 胆管癌 (CCA) 的预后不好,生物标志物和治疗方法有限.
- 铜的失调与CCA有关,但铜载体SLC31A1 (CTR1) 的作用尚不清楚.
研究的目的:
- 研究SLC31A1 (CTR1) 在CCA进展中的作用.
- 探索SLC31A1作为CCA中的潜在生物标志物和治疗标.
主要方法:
- 使用RT-PCR和ELISA评估了CCA组织中的SLC31A1mRNA和蛋白质水平,而不是邻近的非瘤组织.
- 测量了组织铜度,细胞增殖,殖民地形成,ATP水平,ROS产量和GSH/GSSG比率.
- 与临床病理学参数和铜积累相关的SLC31A1表达.
主要成果:
- 在CCA组织中,SLC31A1显著升高调节,并与晚期,较大的瘤大小和微血管入侵有关.
- SLC31A1表达与瘤中铜积累增加相关.
- 沉默SLC31A1抑制了CCA细胞增殖和殖民地形成,破坏了线粒体功能,并损害了氧化还原平衡.
结论:
- SLC31A1通过维持铜恒温,线粒体完整性和氧化还原平衡来促进CCA进展.
- SLC31A1代表了胆管癌的潜在预后生物标志物和治疗点.
相关概念视频
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Carrier-Mediated Transport
1.1K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.1K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
ABC Transporters: Exporter
6.3K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
6.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


